ivosidenib — CareFirst (Caremark)

Initial criteria

• Subsequent treatment of MDS in members with a susceptible IDH1 mutation

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months